Flupentixol (Fluanxol, Depixol): Why This Thioxanthene Is Not in U.S. Pharmacies and What Telehealth Can Still Do

Last updated: August 24, 2026

Flupentixol (also spelled flupenthixol) is a first-generation thioxanthene antipsychotic sold abroad as Fluanxol and Depixol. Clinicians use oral tablets and a long-acting flupentixol decanoate injection for maintenance care in chronic schizophrenia when the main picture is not agitation or hyperactivity. It is not available in the United States. If you or a family member used Fluanxol overseas, a U.S. licensed clinician can still review symptoms, discuss FDA-available alternatives, and plan follow-up by video.

See conditions Klarity clinicians evaluate or learn how online anxiety and related mental health visits work.

TLDR

• Flupentixol is a thioxanthene neuroleptic used for schizophrenia (and, at lower doses in some countries, depression). Brands include Fluanxol and Depixol. See DrugBank DB00875.
• Health Canada’s Fluanxol monograph (Lundbeck, revised Dec 12, 2017) lists oral 0.5 / 3 / 5 mg tablets and depot 20 mg/mL and 100 mg/mL for maintenance of non-agitated chronic schizophrenia. It is not for severely agitated, psychoneurotic, or confused geriatric patients.
• Oral elimination half-life is about 35 hours. Depot release half-life is about 3 weeks; apparent half-life around 17 days means steady state can take about 2 months (Bailey and Taylor 2019).
• A 2019 systematic review found the most useful maintenance depot range is often 20-40 mg every 2 weeks. Cochrane 2014 found little to choose versus other depots, on low-quality data.
• U.S. patients cannot fill Fluanxol here. Telehealth can still evaluate psychosis, anxiety, and depression and discuss medicines that U.S. pharmacies actually stock. Coverage varies by plan; verify benefits before you book.

What people ask about flupentixol

• What is flupentixol (Fluanxol, Depixol)?
• Is Fluanxol available in the United States?
• How do clinicians dose oral and depot flupentixol?
• What does research say about depot dose and benefit?
• What side effects and warnings matter?
• What can U.S. telehealth still do?
• FAQ

What is flupentixol (Fluanxol, Depixol)?

DrugBank describes flupentixol as a thioxanthene neuroleptic used to treat schizophrenia and depression. PubChem CID 5281881 lists formula C23H25F3N2OS, ATC QN05AF01, and an oral elimination half-life of about 35 hours. It also binds 5-HT2C receptors. Common brand names outside the U.S. are Fluanxol (Lundbeck) and Depixol (widely used in the UK).

The Canadian product monograph states Fluanxol tablets and Fluanxol Depot are indicated for maintenance therapy of chronic schizophrenic patients whose main manifestations do not include excitement, agitation, or hyperactivity (Health Canada / Lundbeck, Dec 12, 2017). It is contraindicated in known thioxanthene or phenothiazine hypersensitivity, alcohol/barbiturate/opiate intoxication, CNS depression or coma, liver damage, cerebrovascular or renal insufficiency, and severe cardiovascular disease. It is not indicated for severely agitated psychosis, psychoneurosis, or geriatric confusion/agitation, and is not recommended under age 18.

That “not for agitation” line is the clinical personality of the drug. Phenothiazines such as chlorpromazine are more sedating. Flupentixol is often described as less sedating, which is why labels steer it toward quieter, chronic pictures rather than acute excitement.

Is Fluanxol available in the United States?

No commercial U.S. product is on pharmacy shelves. UpToDate lists flupentixol as “United States: Not available.” A 2022 practical LAI review notes flupentixol decanoate and zuclopenthixol decanoate among first-generation long-acting injectables approved in the EU but not in the U.S. (PMC9809355). LiverTox, discussing a Danish case, likewise calls Depixol “a thioxanthene antipsychotic not available in the US” (NBK548610).

People search “flupentixol” and “Fluanxol” after a move from Canada, the UK, Australia, or Europe, or after a family member’s depot clinic. The U.S. answer is substitution with an FDA-available oral or long-acting antipsychotic, not a Fluanxol transfer. Do not import unlabeled depot ampoules. A clinician who is licensed in your state should redesign the plan.

Browse condition pages if you need a starting point for what a visit can cover.

How do clinicians dose oral and depot flupentixol?

These figures are from the Canadian Fluanxol monograph. They are not a U.S. prescribing guide.

Oral tablets (0.5, 3, and 5 mg as dihydrochloride). Initial recommended dose is 1 mg three times a day, increased by 1 mg every 2 to 3 days if needed. Usual maintenance is 3 to 6 mg daily in divided doses; some patients have used 12 mg daily or more. After stabilization, many people switch to depot. Conversion: x mg oral daily corresponds to 4x mg decanoate every 2 weeks, or 8x mg every 4 weeks. Example: 3 mg oral daily corresponds to 12 mg depot every 2 weeks or 24 mg every 4 weeks. Oral flupentixol continues during the first week after the first injection, in a diminishing dose.

Depot (20 mg/mL and 100 mg/mL decanoate in medium-chain triglycerides). Deep intramuscular injection into the gluteal region only; not intravenous. Onset usually 24-72 hours; improvement continues for 2-4 weeks. Patients new to depots: test dose 5-20 mg of the 2% product (5 mg if elderly, frail, cachectic, or EPS-prone). Patients already tolerant of other depots: 20-40 mg may be adequate. A second 20-40 mg dose can follow in 4-10 days. Most people are controlled on 20-40 mg every 2-3 weeks. Doses above 80 mg of the 2% product are usually not necessary. Unit increments should not exceed 20 mg. Volumes over 2 mL should be split across two sites. Cross-depot ratios in the monograph: 40 mg flupentixol decanoate ≈ 25 mg fluphenazine decanoate ≈ 200 mg zuclopenthixol decanoate ≈ 50 mg haloperidol decanoate.

Pharmacokinetics. Oral T½β about 35 hours. Depot: half-life reflecting release about 3 weeks; half-life from excretion data about 8 days for the injection. Bailey and Taylor calculate an average apparent half-life of 17 days and time to steady state around 2 months, which is why they prefer oral titration first.

What does research say about depot dose and benefit?

Bailey and Taylor (Psychopharmacology, 2019) reviewed maintenance studies. Mean doses in the literature ran from 10 to 333 mg every 2 weeks (average 46.2 mg/2 weeks). Six-month treatment success averaged 85.4% (range 62.5-100%). Effect flattened between about 20 and 40 mg every 2 weeks, and more clearly beyond 30 mg/2 weeks when studies that allowed extra antipsychotics were excluded. EPSE rates in reporting studies ran 12-71% in that dose band, with no significant correlation between dose and EPSE in their plot. They suggest starting depot at 20 mg every 2 weeks, considering 30-40 mg after 8 weeks if needed, and reserving doses above 100 mg/2 weeks for exceptional cases. They argue the UK Depixol label’s very wide range should move closer to Fluanxol’s tighter range.

The Cochrane review of depot flupenthixol decanoate (Mahapatra, Quraishi, David, Sampson, Adams, 2014; 15 trials, 626 people) concluded there is nothing to choose between this depot and other depot antipsychotics on the data reported, and that standard dose rather than high dose is reasonable because relapse did not differ. All evidence was low or very low quality. One small oral comparison (penfluridol, n = 60) showed no clear difference on leaving early or anticholinergic use (PMC7057031).

That is a fair way to talk about Fluanxol in 2026: a widely used non-U.S. depot with a plausible mid-range dose, not a miracle or a uniquely dangerous outlier versus other first-generation injectables.

What side effects and warnings matter?

The monograph’s boxed-style warning covers neuroleptic malignant syndrome (rare, sometimes fatal). Analyses of atypical antipsychotics in elderly dementia showed about a 1.6-fold increase in death; observational data suggest conventional agents may share that risk. Flupentixol is not indicated in dementia.

Common effects overlap other first-generation antipsychotics: fatigue, dry mouth, dizziness, weight change, constipation, sweating, photosensitivity, insomnia, sialorrhea, injection-site pain, muscle spasm or stiffness. Serious risks include hypotension, tachycardia, EPS, tardive dyskinesia, prolactin effects, seizures, priapism, and liver injury signals. Phenothiazine-class liver injury is better documented than thioxanthene injury; LiverTox still treats the family with caution and notes one patient who tolerated Depixol long term after chlorpromazine jaundice.

Do not stop a depot abruptly without a clinician. Apparent half-life of weeks means both benefit and adverse effects fade slowly, and a sudden gap can unmask relapse.

What can U.S. telehealth still do?

Klarity cannot dispense Fluanxol. A visit can still:

• Take a structured history of psychosis, mood, anxiety, sleep, and prior medicines (including overseas depots).
• Discuss FDA-available oral or long-acting options and monitoring (EPS, metabolic labs, ECG when indicated).
• Coordinate in-person labs or injections when a U.S. LAI is appropriate.
• Support anxiety and depression that often travel with a schizophrenia diagnosis.

HHS last updated telehealth policy on February 5, 2026. Medicare patients can permanently receive behavioral/mental telehealth in the home, without geographic originating-site limits, including audio-only when video is not possible. The six-month in-person requirement for Medicare behavioral telehealth is waived through December 31, 2027 (Telehealth.HHS.gov policy updates).

Klarity’s network includes 2,000+ licensed providers. Insurance may help pay for a visit; coverage varies by plan, state, and whether the clinician is in network. Verify benefits before you book. This article is education, not a diagnosis or a promise that any medicine will be prescribed.

If you are in crisis, call or text 988 (U.S. Suicide & Crisis Lifeline) or go to the nearest emergency department.

See if an online mental health visit may be a fit.

FAQ

Is flupentixol the same as fluphenazine?

No. Fluphenazine is a phenothiazine with U.S. products. Flupentixol is a thioxanthene sold as Fluanxol/Depixol abroad. Depot conversion tables treat them as different milligram strengths (40 mg flupentixol decanoate ≈ 25 mg fluphenazine decanoate in the Canadian monograph).

Can a U.S. telehealth clinician restart my Fluanxol depot?

Not from a U.S. retail pharmacy. The visit is for evaluation and a plan that uses medicines available here.

Does insurance cover a visit to talk about this?

It may. Plans differ on telehealth, mental health parity, and prior authorization. Ask your insurer what they pay for an outpatient psychiatry or primary-care video visit.

What about zuclopenthixol (Clopixol)?

That is a related thioxanthene, also generally unavailable in the U.S. It needs its own clinical discussion; do not interchange depots without a prescriber who knows both labels.

Sources

• DrugBank DB00875, Flupentixol
• PubChem CID 5281881
• Fluanxol / Fluanxol Depot product monograph, Lundbeck Canada, Dec 12, 2017
• Bailey L, Taylor D. Psychopharmacology. 2019;236:3081-3092
• Mahapatra et al. Cochrane Database Syst Rev. 2014
• Practical guidance on LAIs, 2022
• LiverTox: Fluphenazine (Depixol note)
• HHS telehealth policy updates, Feb 5, 2026

Disclaimer: Coverage and prescribing vary by plan, state law, and clinical judgment. This page does not say your insurance will pay for any medicine or visit. Confirm benefits with your plan. Klarity does not provide emergency care.